Ra Medical Systems to Report 2021 Fourth Quarter and Full Year Financial Results on March 23, 2022

Rhea-AI Summary

Ra Medical Systems (NYSE American: RMED) will announce its 2021 fourth quarter and full year financial results on March 23, 2022, after market close. An investment community conference call will follow at 1:30 p.m. PT (4:30 p.m. ET) to discuss these results and provide updates. Participants can pre-register for the call and access it via phone or a live webcast, which will also be archived for 30 days. Ra Medical is known for its DABRA excimer laser system used in treating vascular diseases, with FDA and CE mark clearances for various applications.

Positive

• Scheduled announcement of 2021 financial results may attract investor interest.
• DABRA excimer laser system has FDA and CE mark approvals, enhancing market credibility.

Negative

• None.

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ra Medical Systems, Inc. (NYSE American: RMED) announces that it will report 2021 fourth quarter and full year financial results after market close on Wednesday, March 23. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update.

Pre-Registration		Participants can pre-register for the conference call here
		Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
Live Call:		Those who choose not to pre-register can access the live conference by dialing:
		U.S.	866-777-2509
		International	412-317-5413
		Request to join the Ra Medical Systems conference call
Live Webcast:		Ra Medical Systems Website
		The webcast will be archived for 30 days.
Replay:		U.S.	877-344-7529
		Canada	855-669-9658
		International	412-317-0088
		Passcode	9255498
		The replay will be available for 48 hours

About Ra Medical Systems

Ra Medical Systems manufactures the DABRA excimer laser and catheters for the treatment of certain vascular diseases. DABRA has been cleared by the FDA for crossing chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease and has an intended use for ablating a channel in occlusive peripheral vascular disease. In addition, DABRA has been granted CE mark clearance for the endovascular treatment of infrainguinal arteries via atherectomy and for crossing total occlusions. DABRA excimer lasers and catheters are manufactured in a 32,000-square-foot facility located in Carlsbad, California. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in clean room environments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220315006115/en/

At the Company:

Andrew Jackson

Chief Financial Officer, Ra Medical Systems

760-496-9540

ajackson@ramed.com

Investors:

LHA Investor Relations

Jody Cain

310-691-7100

jcain@lhai.com

Source: Ra Medical Systems, Inc.

FAQ

When will Ra Medical Systems report its financial results for 2021?

Ra Medical Systems will report its financial results for 2021 after market close on March 23, 2022.

What is the time for the Ra Medical Systems conference call?

The conference call for Ra Medical Systems is scheduled for 1:30 p.m. PT on March 23, 2022.

How can I access the Ra Medical Systems financial results call?

You can access the Ra Medical Systems financial results call by pre-registering or by dialing the provided numbers for U.S. and international callers.

What products does Ra Medical Systems manufacture?

Ra Medical Systems manufactures the DABRA excimer laser and catheters for treating vascular diseases.